Revolutionizing Alzheimer's disease and clinical trials through biomarkers

Niklas Mattsson, Maria C. Carrillo, Robert A. Dean, Michael D. Devous, Tania Nikolcheva, Pedro Pesini, Hugh Salter, William Z. Potter, Reisa S. Sperling, Randall J. Bateman, Lisa J. Bain, Enchi Liu

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.

Original languageEnglish (US)
Pages (from-to)412-419
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume1
Issue number4
DOIs
StatePublished - Dec 1 2015

Fingerprint

Alzheimer Disease
Biomarkers
Clinical Trials
Positron-Emission Tomography
Magnetic Resonance Imaging
Ligands
Research
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Amyloid
  • Biomarkers
  • Blood biomarkers
  • Cerebrospinal fluid
  • Clinical trials
  • CSF
  • Imaging
  • MRI
  • PET
  • Tau

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., ... Liu, E. (2015). Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 1(4), 412-419. https://doi.org/10.1016/j.dadm.2015.09.001

Revolutionizing Alzheimer's disease and clinical trials through biomarkers. / Mattsson, Niklas; Carrillo, Maria C.; Dean, Robert A.; Devous, Michael D.; Nikolcheva, Tania; Pesini, Pedro; Salter, Hugh; Potter, William Z.; Sperling, Reisa S.; Bateman, Randall J.; Bain, Lisa J.; Liu, Enchi.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 1, No. 4, 01.12.2015, p. 412-419.

Research output: Contribution to journalArticle

Mattsson, N, Carrillo, MC, Dean, RA, Devous, MD, Nikolcheva, T, Pesini, P, Salter, H, Potter, WZ, Sperling, RS, Bateman, RJ, Bain, LJ & Liu, E 2015, 'Revolutionizing Alzheimer's disease and clinical trials through biomarkers', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 1, no. 4, pp. 412-419. https://doi.org/10.1016/j.dadm.2015.09.001
Mattsson, Niklas ; Carrillo, Maria C. ; Dean, Robert A. ; Devous, Michael D. ; Nikolcheva, Tania ; Pesini, Pedro ; Salter, Hugh ; Potter, William Z. ; Sperling, Reisa S. ; Bateman, Randall J. ; Bain, Lisa J. ; Liu, Enchi. / Revolutionizing Alzheimer's disease and clinical trials through biomarkers. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2015 ; Vol. 1, No. 4. pp. 412-419.
@article{6380671387e34573b491d956c47563a4,
title = "Revolutionizing Alzheimer's disease and clinical trials through biomarkers",
abstract = "The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.",
keywords = "Alzheimer's disease, Amyloid, Biomarkers, Blood biomarkers, Cerebrospinal fluid, Clinical trials, CSF, Imaging, MRI, PET, Tau",
author = "Niklas Mattsson and Carrillo, {Maria C.} and Dean, {Robert A.} and Devous, {Michael D.} and Tania Nikolcheva and Pedro Pesini and Hugh Salter and Potter, {William Z.} and Sperling, {Reisa S.} and Bateman, {Randall J.} and Bain, {Lisa J.} and Enchi Liu",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.dadm.2015.09.001",
language = "English (US)",
volume = "1",
pages = "412--419",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Revolutionizing Alzheimer's disease and clinical trials through biomarkers

AU - Mattsson, Niklas

AU - Carrillo, Maria C.

AU - Dean, Robert A.

AU - Devous, Michael D.

AU - Nikolcheva, Tania

AU - Pesini, Pedro

AU - Salter, Hugh

AU - Potter, William Z.

AU - Sperling, Reisa S.

AU - Bateman, Randall J.

AU - Bain, Lisa J.

AU - Liu, Enchi

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.

AB - The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.

KW - Alzheimer's disease

KW - Amyloid

KW - Biomarkers

KW - Blood biomarkers

KW - Cerebrospinal fluid

KW - Clinical trials

KW - CSF

KW - Imaging

KW - MRI

KW - PET

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84946048255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946048255&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2015.09.001

DO - 10.1016/j.dadm.2015.09.001

M3 - Article

C2 - 27239522

AN - SCOPUS:84946048255

VL - 1

SP - 412

EP - 419

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

IS - 4

ER -